莫西沙星（moxifloxacin）作為第四代喹諾酮類超廣譜抗菌藥，其最低抑菌濃度低、抗耐藥特性較強(qiáng)，在抗結(jié)核藥物中具優(yōu)勢和潛力。耐藥結(jié)核菌群不斷出現(xiàn)、一線藥物臨床療效下降、患者順應(yīng)性差等使結(jié)核病臨床治愈率低。為此，開發(fā)適合肺部介入給藥的莫西沙星緩釋制劑，以減少給藥次數(shù)、增加患者順應(yīng)性，具有理論意義與臨床價值。綜述近年來出現(xiàn)的脂質(zhì)體、微球、納米粒子等莫西沙星緩控釋制劑的國內(nèi)外研究進(jìn)展，為新藥研發(fā)提供依據(jù)。

Moxifloxacin (MXF) is a novel fourth generation fluoroquinolone with a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, anaerobes, and atypical organisms, the lower MIC value and high antibacterial effects make it a suitable antibiotic for treating various infectious diseases. The drug-resistant strains, the clinical efficacy decline of the first-line drugs including isoniazid and rifampicin equality, and the decreasing of resistance of patients push the therapy of the infection caused by drug-resistant strains in an embarrassing place. Therefore, it is imperative to research the MXF controlled-release preparation for pulmonary intervention therapy to decrease the dosage and improve the patient’s compliance. The paper summarizes the study progress on MXF controlled-release preparation such as liposome, microsphere, and nanoparticle, both in China and abroad.

重大傳染病專項（2012ZX10003009-001-002）